Roy Shuvam, Kaul Anupma, Bhadhuria Dharmendra Singh, Prasad Narayan, Garg Atul, Marak Rungmei S K, Patel Manas Ranjan, Behera Manas Ranjan, Kushwaha Ravi Shankar, Yachha Monika
Department of Nephrology and Renal Transplantation, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India.
Department of Nephrology and Renal Transplantation, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India.
Transpl Immunol. 2024 Jun;84:102040. doi: 10.1016/j.trim.2024.102040. Epub 2024 Mar 31.
Reactivation of cytomegalovirus (CMV) infection in transplant patients is high because of immunosuppression. We have evaluated the clinical and epidemiological characteristics of early versus late onset of CMV infection among renal transplant recipients.
A single center retrospective observational study was conducted among renal transplant recipients who underwent kidney transplant between January 2002 and December 2021. CMV disease was classified as early or late depending on its detection prior to or after 90 days post-transplantation. Herein, we reported the differences between early and late onset of CMV disease with respect to clinical symptoms, the use of immunosuppression and the impact on graft outcomes.
Out of total 2164 renal transplant recipients, 156 patients (7.2%) were diagnosed with CMV disease. Among these 156 patients, 25 patients (16%) had early CMV while 131 patients (84%) had late CMV. Overall, the two groups did not differ with respect to the induction or maintenance of immunosuppressive agents. However, the proportion of CMV syndrome was greater among early (56.0%) than late (26.7%) CMV groups (p = 0.01). In contrast, tissue invasive disease was more frequent among late (73.3%) in comparison to early (44.0%) CMV groups (p = 0.01). Among clinical symptoms, diarrhea was more frequent in late (63.4%) vs. early (36%) CMV-affected patients (p = 0.01). Graft loss occurred in 4.0% of early CMV group vs. 25.2% of late CMV group (p = 0.03). Neither of the clinical groups differed with respect to occurrence of biopsy-proven allograft rejection post-infection.
Early CMV disease presents more frequently as CMV syndrome while late CMV disease usually manifests itself as tissue invasive disease. Graft loss is more common in patients with late onset of CMV disease.
由于免疫抑制,移植患者中巨细胞病毒(CMV)感染的再激活率很高。我们评估了肾移植受者中CMV感染早发与晚发的临床和流行病学特征。
对2002年1月至2021年12月期间接受肾移植的肾移植受者进行了一项单中心回顾性观察研究。根据移植后90天之前或之后检测到CMV疾病,将其分为早发型或晚发型。在此,我们报告了CMV疾病早发和晚发在临床症状、免疫抑制的使用以及对移植结局的影响方面的差异。
在总共2164例肾移植受者中,156例患者(7.2%)被诊断为CMV疾病。在这156例患者中,25例(16%)为早发型CMV,131例(84%)为晚发型CMV。总体而言,两组在免疫抑制剂的诱导或维持方面没有差异。然而,早发型CMV组中CMV综合征的比例(56.0%)高于晚发型CMV组(26.7%)(p = 0.01)。相反,与早发型CMV组(44.0%)相比,晚发型CMV组(73.3%)中组织侵袭性疾病更为常见(p = 0.01)。在临床症状方面,晚发型CMV感染患者(63.4%)出现腹泻的频率高于早发型CMV感染患者(36%)(p = 0.01)。早发型CMV组的移植丢失率为4.0%,晚发型CMV组为25.2%(p = 0.03)。两个临床组在感染后经活检证实的同种异体移植排斥反应的发生率方面没有差异。
早发型CMV疾病更常表现为CMV综合征,而晚发型CMV疾病通常表现为组织侵袭性疾病。CMV疾病晚发患者的移植丢失更为常见。